| 2024-03-28 | +139.6% | M&A | Seeking Alpha | Xilio stock jumps on Gilead Sciences license deal |
| 2024-03-28 | +139.6% | news | Seeking Alpha | Xilio Therapeutics announces $11.3 million private placement equity financing |
| 2024-03-28 | +139.6% | legal | SEC EDGAR | XLO 8-K: 8.01 (SEC Filing) |
| 2024-03-28 | +139.6% | legal | SEC EDGAR | XLO 8-K: 1.01, 2.02, 2.05, 3.02, 7.01, 8.01 (SEC Filing) |
| 2024-03-28 | +139.6% | news | InvestorPlace | Why Is Xilio Therapeutics (XLO) Stock up 168% Today? - InvestorPlace |
| 2025-02-12 | +95.6% | expansion | Seeking Alpha | AbbVie and Xilio Therapeutics announce collaboration and option agreement |
| 2025-02-12 | +95.6% | legal | SEC EDGAR | XLO 8-K: 1.01, 3.02, 7.01, 8.01 (SEC Filing) |
| 2024-03-27 | +63.1% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2024-12-19 | +46.8% | legal | SEC EDGAR | XLO 8-K: 3.02, 7.01, 8.01 (SEC Filing) |
| 2024-12-19 | +46.8% | legal | Stock Titan | Xilio Therapeutics Reports Promising Safety Data for Cancer Drug XTX301, Secures $25M Gilead Investment - Stock Titan |
| 2025-06-02 | -38.0% | news | Seeking Alpha | Xilio Therapeutics announces pricing of $50 million public offering |
| 2025-06-02 | -38.0% | news | Seeking Alpha | Xilio Therapeutics announces public offering; shares down |
| 2025-06-02 | -38.0% | legal | SEC EDGAR | XLO 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-04-01 | +37.8% | earnings | Seeking Alpha | Xilio Therapeutics reports Q4 results |
| 2024-04-01 | +37.8% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2024-01-03 | +27.2% | legal | SEC EDGAR | XLO 8-K: 5.02 and (SEC Filing) |
| 2022-08-09 | -26.4% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.90 |
| 2022-08-09 | -26.4% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2024-11-07 | -24.5% | legal | SEC EDGAR | XLO 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2024-11-07 | -24.5% | earnings | Stock Titan | Xilio Therapeutics Q3 Revenue Hits $2.3M, Cuts Losses Amid Clinical Progress - Stock Titan |
| 2025-01-21 | -23.4% | legal | SEC EDGAR | XLO 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-11-09 | -23.1% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2021-12-07 | -21.1% | news | Seeking Alpha | Xilio sheds over fifth in value to extend losses to fourth straight session |
| 2021-12-02 | -20.9% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2022-12-23 | +20.4% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2022-03-01 | -19.4% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.98 misses by $0.06 |
| 2022-03-01 | -19.4% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2025-05-13 | +15.5% | news | StocksToTrade | Xilio Therapeutics: Is a Breakthrough Happening? - StocksToTrade |
| 2023-11-03 | -14.7% | legal | SEC EDGAR | XLO 8-K: 8.01 and (SEC Filing) |
| 2022-03-07 | -14.6% | news | Seeking Alpha | Xilio Therapeutics (XLO) Investor Presentation - Slideshow |
| 2023-11-10 | -13.3% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.61 |
| 2022-04-26 | -12.8% | news | ChartMill | XLO Stock Price, Quote & Chart | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill |
| 2022-09-15 | +12.2% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2026-02-11 | +11.5% | M&A | Stock Titan | Cancer drug developer Xilio raises $40M in warrant deal - Stock Titan |
| 2026-02-12 | +9.9% | news | GlobeNewswire | Xilio Therapeutics Announces Pricing of Underwritten Offering |
| 2026-02-12 | +9.9% | news | Seeking Alpha | Xilio Therapeutics prices $40M stock offering |
| 2026-02-12 | +9.9% | legal | SEC EDGAR | XLO 8-K: 1.01, 7.01 (SEC Filing) |
| 2026-02-12 | +9.9% | news | Quiver Quantitative | Xilio Therapeutics Announces Pricing of $40 Million Underwritten Offering of Pre-Funded Warrants - Quiver Quantitative |
| 2023-03-02 | -7.1% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.82 misses by $0.08 |
| 2023-03-02 | -7.1% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | -6.9% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M |
| 2025-11-13 | -6.9% | legal | SEC EDGAR | XLO 8-K: 2.02 (SEC Filing) |
| 2022-05-12 | +6.8% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.78 beats by $0.21 |
| 2022-05-12 | +6.8% | legal | SEC EDGAR | XLO 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-13 | +6.6% | news | MSN | Xilio Therapeutics announces 1-for-14 reverse stock split - MSN |
| 2025-09-09 | +5.9% | legal | SEC EDGAR | XLO 8-K: 8.01 and (SEC Filing) |
| 2025-05-08 | +5.9% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.18 misses by $0.28 |
| 2025-05-08 | +5.9% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2026-03-23 | +5.8% | news | GlobeNewswire | Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-23 | +5.8% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2026-03-23 | +5.8% | news | GlobeNewswire | Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire |
| 2026-03-23 | +5.8% | news | Stock Titan | Cancer drug developer targets 2026 trial start with cash into 2027 - Stock Titan |
| 2023-05-25 | -5.6% | legal | SEC EDGAR | XLO 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-11-08 | +5.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Xilio Therapeutics (XLO) - Zacks Investment Research |
| 2025-06-03 | -5.4% | legal | SEC EDGAR | XLO 8-K: 1.01, 7.01, 8.01 (SEC Filing) |
| 2022-06-16 | -5.3% | legal | SEC EDGAR | XLO 8-K: 5.02 and (SEC Filing) |
| 2024-05-11 | -5.1% | earnings | MarketBeat | Xilio Therapeutics (XLO) Stock Forecast and Price Target 2026 $XLO - MarketBeat |
| 2026-03-09 | +4.9% | news | Stock Titan | Cash runway to 2027: Xilio Therapeutics (NASDAQ: XLO) details I-O pipeline - Stock Titan |
| 2023-12-07 | -4.9% | legal | SEC EDGAR | XLO 8-K: 8.01 and (SEC Filing) |
| 2022-02-04 | +4.6% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2024-11-08 | +4.3% | earnings | Seeking Alpha | Xilio Therapeutics reports Q3 results |
| 2025-11-11 | -4.3% | news | Seeking Alpha | Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow |
| 2025-11-11 | -4.3% | news | Seeking Alpha | Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript |
| 2026-01-08 | -4.2% | legal | SEC EDGAR | XLO 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-01-08 | -4.2% | news | Stock Titan | Biotech Xilio brings in $35.8M to advance masked cancer therapies - Stock Titan |
| 2024-06-13 | -4.0% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2022-01-06 | -3.7% | legal | SEC EDGAR | XLO 8-K: 5.02 and (SEC Filing) |
| 2021-11-22 | -3.5% | news | StockInvest.us | Xilio Therapeutics Stock Price Forecast. Should You Buy XLO? - StockInvest.us |
| 2026-03-12 | -3.5% | news | GlobeNewswire | Xilio Therapeutics Announces 1-for-14 Reverse Stock Split |
| 2026-03-12 | -3.5% | news | Seeking Alpha | Xilio Therapeutics announces 1-for-14 reverse stock split |
| 2026-03-12 | -3.5% | news | GlobeNewswire | Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - GlobeNewswire |
| 2026-03-12 | -3.5% | news | Stock Titan | Cancer biotech Xilio enacts 1-for-14 reverse split to regain Nasdaq compliance - Stock Titan |
| 2026-03-12 | -3.5% | news | TipRanks | Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - TipRanks |
| 2022-07-28 | -3.4% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2023-08-14 | +3.1% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.70 |
| 2023-08-14 | +3.1% | legal | SEC EDGAR | XLO 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-03-17 | +2.7% | news | CoinCodex | Xilio Therapeutics, Inc. (XLO) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2025-05-26 | -2.6% | news | Intellectia AI | XLO Forecast — Price Prediction for 2026. Should I Buy XLO? - Intellectia AI |
| 2021-10-25 | +2.2% | news | Zacks Investment Research | Xilio Therapeutics - XLO - Stock Price Today - Zacks Investment Research |
| 2021-10-25 | +2.2% | news | Zacks Investment Research | Should I buy Xilio Therapeutics (XLO) - Zacks Investment Research |
| 2021-10-25 | +2.2% | earnings | Zacks Investment Research | What date does Xilio Therapeutics's (XLO) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2024-08-08 | -2.2% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M |
| 2024-08-08 | -2.2% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2022-11-09 | +2.2% | legal | SEC EDGAR | XLO 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-09 | +2.1% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.83 beats by $0.06 |
| 2023-05-09 | +2.1% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2025-03-11 | -2.1% | earnings | Seeking Alpha | Xilio Therapeutics reports Q4 results |
| 2025-03-11 | -2.1% | legal | SEC EDGAR | XLO 8-K: 1.01 and (SEC Filing) |
| 2025-03-11 | -2.1% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2026-02-25 | -1.9% | news | The Globe and Mail | Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split - The Globe and Mail |
| 2025-11-25 | -1.9% | legal | SEC EDGAR | XLO 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-11-25 | -1.9% | news | Stock Titan | [Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan |
| 2024-05-14 | -1.7% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.62 |
| 2024-05-14 | -1.7% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2025-04-24 | +1.6% | news | Stock Titan | XLO Stock Price, News & Analysis - Stock Titan |
| 2026-04-12 | -1.6% | expansion | marketscreener.com | Certain Common Stock of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com |
| 2026-03-30 | -1.5% | news | Stock Titan | [Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan |
| 2025-06-10 | -1.3% | legal | SEC EDGAR | XLO 8-K: 5.02 (SEC Filing) |
| 2026-04-22 | -1.2% | news | Stock Titan | XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan |
| 2026-04-18 | -1.2% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18 - Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2023-04-03 | +1.1% | legal | SEC EDGAR | XLO 8-K: 5.02, 5.03 (SEC Filing) |
| 2023-09-05 | +1.1% | legal | SEC EDGAR | XLO 8-K: 5.02, 8.01 (SEC Filing) |
| 2023-08-03 | +1.1% | executive | Seeking Alpha | Xilio Therapeutics announces promotion of Chris Frankenfield to chief operating officer |
| 2023-08-03 | +1.1% | legal | SEC EDGAR | XLO 8-K: 5.02 and (SEC Filing) |
| 2026-04-03 | -1.1% | news | GlobeNewswire | Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-03 | -1.1% | news | GlobeNewswire | Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire |
| 2026-04-03 | -1.1% | news | Stock Titan | Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan |
| 2026-03-26 | +1.0% | news | Zacks | Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market |
| 2021-10-26 | +0.9% | news | Stock Titan | Latest XLO News - Xilio Therapeutics Announces New Preclinical... - Stock Titan |
| 2026-03-02 | +0.8% | news | GlobeNewswire | Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference |
| 2026-03-02 | +0.8% | news | Stock Titan | Biotech Xilio gives new cancer-drug hires 50,050 stock options - Stock Titan |
| 2023-03-09 | +0.8% | news | Seeking Alpha | Xilio Therapeutics (XLO) Investor Presentation - Slideshow |
| 2022-12-11 | +0.7% | analyst | ChartMill | XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill |
| 2025-08-14 | -0.6% | earnings | Seeking Alpha | Xilio Therapeutics GAAP EPS of -$0.16 misses by $0.06 |
| 2025-08-14 | -0.6% | legal | SEC EDGAR | XLO 8-K: 2.02 and (SEC Filing) |
| 2022-11-12 | -0.6% | news | Seeking Alpha | Xilio Therapeutics (XLO) Investor Presentation - Slideshow |
| 2026-04-16 | +0.6% | executive | GlobeNewswire | Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors |
| 2026-04-16 | +0.6% | legal | SEC EDGAR | XLO 8-K: 5.02 and (SEC Filing) |
| 2026-04-16 | +0.6% | news | Stock Titan | Xilio Therapeutics (XLO) grants director 10,000 stock options at $8.40 - Stock Titan |
| 2026-04-16 | +0.6% | news | Stock Titan | Xilio brings in a 30-year biotech veteran as board member - Stock Titan |
| 2026-04-16 | +0.6% | news | Stock Titan | Xilio Therapeutics (NASDAQ: XLO) adds Cheryl Blanchard to board roles - Stock Titan |
| 2026-04-16 | +0.6% | news | Stock Titan | Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider - Stock Titan |
| 2021-10-23 | -0.5% | earnings | MarketBeat | Xilio Therapeutics (XLO) Stock Price, News & Analysis $XLO - MarketBeat |
| 2026-03-17 | +0.4% | news | GlobeNewswire | Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting |
| 2026-04-01 | +0.3% | analyst | Zacks | Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? |
| 2026-04-01 | +0.3% | analyst | Yahoo Finance | Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance |
| 2022-01-20 | +0.3% | news | Seeking Alpha | Xilio Therapeuticsbegins dosing in phase 1/2 study of XTX202 to treat solid tumors |
| 2026-04-17 | +0.2% | news | GlobeNewswire | Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 |
| 2026-04-17 | +0.2% | news | Stock Titan | Cancer drug candidate showed tumor killing without cytokine syndrome - Stock Titan |
| 2025-07-10 | -0.1% | earnings | MarketBeat | Xilio Therapeutics (XLO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $XLO - MarketBeat |